AR056307A1 - Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas - Google Patents
Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticasInfo
- Publication number
- AR056307A1 AR056307A1 ARP060101362A ARP060101362A AR056307A1 AR 056307 A1 AR056307 A1 AR 056307A1 AR P060101362 A ARP060101362 A AR P060101362A AR P060101362 A ARP060101362 A AR P060101362A AR 056307 A1 AR056307 A1 AR 056307A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- alkoxyalkyl
- hydroxyalkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- -1 pyrroloimidazoyl Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que las contienen. Reivindicacion 1: Un compuesto de formula (1), en la que: R1 representa un heteroarilo seleccionado del grupo que consiste en: imidazolilo, tiazolilo, piridilo, oxazolilo, pirazolilo, triazolilo, oxadiazolilo, quinolinilo, isoxazolilo, pirroloimidazoilo, y tiadiazol, en el que dicho heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados de -OH, -NR7R8, halogeno, alquilo C1-8, cicloalquilo C3-10, alcoxi C1-8, alcoxialquilo C1-12, hidroxialquilo C1-8, arilo C6-14 y bencilo; R2, R3 y A representan independientemente H o alquilo C1-8, en el que dicho alquilo está opcionalmente sustituido con uno o más -OH, alcoxi C1-8, -NR7R8 o halogeno; Q representa - (CH2)n-, en el que n = 1, 2, 3 o 4 o -(CH2)m-O-, en el que m = 2, 3 o 4; Z representa arilo C6-14, alquilo C1-8 o cicloalquilo C3-8; R4 y R5 representan cada uno independientemente H, halogeno, alquilo C1-8, arilo C6-14, ariloxi C6-14, alcoxi C1-8, heterocicloalquilo de 3-10 miembros o cicloalcoxi C3-8; en los que R4 y R5 están opcionalmente sustituidos con uno o más -OH, alcoxi C1-8, -NR7R8 o halogeno; Y representa -R6, -(CH2)o-R6-, -C(R6)3 o -CH(R6)2, en los que o = 1, 2 o 3; R6 representa H, arilo C6-14, alquilo C1-10, cicloalquilo C3-10, bicicloalquilo C5-18, tricicloalquilo C5-18, heterocicloalquilo de 3-10 miembros, heteroarilo de 5-10 miembros, -C(-O)NR7R8, o -C(-O)OR7, en los que dichos grupos R6 pueden estar opcionalmente sustituidos con uno o más grupos X; en los que X = -OH, alcoxi C1-8, -NR11R12, -SO2R10, -C(-O)R10, halogeno, ciano, alquilo C1-8, alcoxialquilo C1-10, heteroarilo de 5-10 miembros, arilo C6-14, ariloxi C6-14, bencilo, o hidroxialquilo C1-8; en los que R7 y R8 representan independientemente H, alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 5-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; en los que R7 y R8 pueden estar opcionalmente sustituidos con uno o más grupos X; o R7 y R8, junto con el nitrogeno al cual pueden estar unidos, pueden formar un grupo heterocicloalquilo de 3-10 miembros opcionalmente sustituido con uno o más grupos X; en los que R10 representa alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 3-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; en los que R11 y R12 representan independientemente H, alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 5-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; o sus sales, solvatos o profármacos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66947205P | 2005-04-08 | 2005-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056307A1 true AR056307A1 (es) | 2007-10-03 |
Family
ID=36649611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101362A AR056307A1 (es) | 2005-04-08 | 2006-04-06 | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060229455A1 (es) |
| EP (1) | EP1869019B1 (es) |
| JP (1) | JP4193949B2 (es) |
| KR (1) | KR100969402B1 (es) |
| CN (1) | CN101189228A (es) |
| AP (1) | AP2007004198A0 (es) |
| AR (1) | AR056307A1 (es) |
| AU (1) | AU2006231917B2 (es) |
| BR (1) | BRPI0608148A2 (es) |
| CA (1) | CA2603939C (es) |
| CR (1) | CR9493A (es) |
| DK (1) | DK1869019T3 (es) |
| DO (1) | DOP2006000078A (es) |
| EA (1) | EA014311B1 (es) |
| ES (1) | ES2520015T3 (es) |
| GE (1) | GEP20105053B (es) |
| GT (1) | GT200600136A (es) |
| HN (1) | HN2006013804A (es) |
| IL (1) | IL186409A (es) |
| MA (1) | MA29672B1 (es) |
| MX (1) | MX2007012463A (es) |
| NL (1) | NL1031539C2 (es) |
| NO (1) | NO339422B1 (es) |
| NZ (1) | NZ563238A (es) |
| PE (1) | PE20061400A1 (es) |
| TN (1) | TNSN07380A1 (es) |
| TW (1) | TW200719890A (es) |
| UA (1) | UA88518C2 (es) |
| UY (1) | UY29456A1 (es) |
| WO (1) | WO2006106425A1 (es) |
| ZA (1) | ZA200708481B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| EP2278879B1 (en) | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
| FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CN102143955B (zh) * | 2008-09-02 | 2013-08-14 | Omj制药公司 | 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物 |
| JP2012503005A (ja) * | 2008-09-19 | 2012-02-02 | インスティテュート フォア ワンワールド ヘルス | イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。 |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8623898B2 (en) | 2009-03-19 | 2014-01-07 | Taisho Pharmaceutical Co., Ltd. | Glycine transporter inhibiting substances |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AR077472A1 (es) * | 2009-07-15 | 2011-08-31 | Taisho Pharmaceutical Co Ltd | Inhibidores de transportador de glicina |
| US8927602B2 (en) | 2009-11-06 | 2015-01-06 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법 |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| WO2012036278A1 (ja) | 2010-09-17 | 2012-03-22 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| JP2013542929A (ja) | 2010-09-28 | 2013-11-28 | パナセア バイオテック リミテッド | 新規ビシクロ環化合物 |
| EP2909181B1 (en) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| MA39888A (fr) | 2014-04-24 | 2017-03-01 | Dart Neuroscience Cayman Ltd | Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 |
| WO2016073420A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| EP3720434A4 (en) | 2017-12-05 | 2021-09-01 | Sunovion Pharmaceuticals Inc. | NON-RACEMIC MIXTURES AND THEIR USE |
| CN113747895A (zh) | 2019-03-22 | 2021-12-03 | 大日本住友制药肿瘤公司 | 包含pkm2调节剂的组合物和用其治疗的方法 |
| AU2020282759A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| PH12021553056A1 (en) | 2019-06-04 | 2023-09-11 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
| CN121041437A (zh) * | 2020-01-09 | 2025-12-02 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| CN116261453A (zh) | 2020-08-13 | 2023-06-13 | 勃林格殷格翰国际有限公司 | 与思觉失调症相关的认知障碍的治疗 |
| KR20230088761A (ko) | 2020-10-13 | 2023-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 재가공하는 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045011A1 (en) | 1998-03-06 | 1999-09-10 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
| JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| WO2003037865A1 (en) | 2001-10-31 | 2003-05-08 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel anticancer compounds |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7473787B2 (en) * | 2003-10-14 | 2009-01-06 | Pfizer Inc | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| CA2904275C (en) | 2004-05-23 | 2020-09-01 | Gerard M. Housey | Theramutein modulators |
-
2006
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/en active Active
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko not_active Expired - Fee Related
- 2006-03-27 CA CA2603939A patent/CA2603939C/en not_active Expired - Fee Related
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/en not_active Ceased
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es active Active
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056307A1 (es) | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| DOP2007000014A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR088534A1 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR054789A1 (es) | Antagonistas del receptor 1 de triazolopiridina canabinoide | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
| AR046982A1 (es) | Derivados de 1-piperazin- y 1-homopiperazin-carboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR083543A1 (es) | Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| CO6220973A2 (es) | Nuevos compuestos triciclicos sustituidos que comprenden 3 a 5 atomos de nitrogeno, derivados de un sistema saturado de 1, 3-diazepina, su preparacion y su utilizacion como medicamentos antibacterianos | |
| ES2438509T3 (es) | Inhibidores de la esfingosina quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |